Dr. Freedland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8635 W 3rd St
Los Angeles, CA 90048Phone+1 310-423-4700Fax+1 310-423-4711
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Urology, 1997 - 2003
- University of California, Davis, School of MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 1999 - 2025
- NC State Medical License 2005 - 2015
- MD State Medical License 2003 - 2006
- American Board of Urology Urology
Publications & Presentations
PubMed
- Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.Neal D Shore, Ugo De Giorgi, Stephen J Freedland
The Journal of Urology. 2025-01-01 - Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recur...Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka
Future Oncology. 2024-12-12 - Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer.Neeraj Agarwal, Daniel J George, Zachary Klaassen, Rickard Sandin, Jake Butcher
JAMA Network Open. 2024-12-02
Press Mentions
- Diet Matters in Prostate Cancer, but It’s ComplicatedNovember 27th, 2024
- Experts Focus on Quality-of-Life Data in Prostate CancerJune 26th, 2024
- Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong BenefitDecember 20th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: